非小细胞肺癌组织中VEGF与P53蛋白表达及意义

目的:探讨VEGF和P53在非小细胞肺癌(NSCLC)中的表达及其生物学行为的关系。方法:采用免疫组织化学方法,对病理确诊的62例非小细胞肺癌组织进行VEGF和P53表达的检测。结果:62例非小细胞肺癌VEGF阳性表达率58.1%(36/62),其表达与NSCLC的组织分化程度、生存期有相关性(P<0.05),与组织学类型、有无淋巴结转移、临床病理分期无关。P53阳性表达率46.8%(29,62),表达与肿瘤组织类型、TNM分期、有无淋巴结转移无关(P<0.05)。结论:VEGF和P53可作为评价非小细胞肺癌预后的重要指标。用免疫组化检测出P53蛋白可间接反映P53基因的突变。本组资料检测的结果显示,P53基因阳性表达率46.8% (29/62),表明近一半肺癌病例已失去P53蛋白的抑癌功能,且P53基因的突变可能与非小细胞肺癌的发生有关。P53和VEGF都是潜在的新型肿瘤表型标志物,它们的检测可作为肿瘤病理分级诊断的主要参考依据。同时检测P53和VEGF的表达状态,可通过肿瘤血管形成的生物学行为信息,进一步研究肿瘤血管形成的分子水平调控机制,这有助于抗肿瘤药物的开发研究。     

survivin在非小细胞肺癌中的表达及其与bcl-2、p63表达的关系

目的：探讨survivin在非小细胞肺癌组织（non small cell lung cancer,NSCLC）中的表达,及其与bcl2、p63蛋白表达的相关性。方法：应用二步法免疫组织化法,检测survivin、bcl-2、p63蛋白在60例NSCLC组织和20例正常肺组织中的表达。结果：肺癌组织中的survivin蛋白阳性率（56．67％）明显高于正常肺组织15％）,有显著性差异;（p〈0．05）Ⅲ期surviving蛋白阳性表达率72．73％（16／22）明显高于Ⅰ＋Ⅲ期survivin47．37％（18／38）。有显著差异;（p〈0．05）survivin蛋白表达与患者年龄、病理类型、组织分化程度,淋巴结转移情况无关（P〉0．05）NSCLC组织bc 1-2蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为66．67％（18／27）和48．48％（16／33）,两者比较,差异有显著性（P〈0．05）;p63蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为53-33％（16／30）和60％（18／30）,两者比较,差异有显著性（P〈0．05）survivin,蛋白与bc1．2蛋白的表达呈正相关。survivin蛋白与p63蛋白的表达呈正相关。结论：survivin在NSCLC组织中表达上调,通过抑制细胞凋亡,在NSCLC的发生和发展中起到重要作用。survivin,bcl-2与p63它们分别在肺癌发生发展过程中不同途径上抑制肺癌细胞的凋亡,对肺癌早期诊断有一定的意义。对3种蛋白进行联合检测,更有利于肺癌的早期诊断和判断肺癌的分化程度、临床分期、淋巴结是否转移及病人的预后。survivin与bcl-2及survivin与p63可能起协同作用、并可能会成为NSCLC基因治疗的新靶点。     

内质网应激分子GRP78 对非小细胞肺癌的诊断价值研究

目的:探讨内质网应激分子葡萄糖调节蛋白78(GRP78)对非小细胞肺癌(NSCLC)的诊断价值。方法:收集45例NSCLC患者术后癌组织标本,及其18例癌旁组织,采用实时定量PCR法检测所有组织中GRP78的表达情况,分析NSCLC癌组织中GRP78的表达与患者临床特征的关系,及其对患者生存期的影响。结果:NSCLC组织中GRP78高表达率明显高于癌旁组织,差异有统计学意义(P0.05)。而Ⅲa期NSCLC患者癌组织中GRP78的表达水平明显高于Ⅰ-Ⅱ期,两者存在显著性的差异(P0.05)。Kaplan-Meier分析显示,GRP78高表达的患者其生存期明显低于GRP78低表达的患者(P0.05)。结论:NSCLC患者GRP78的表达可能与肿瘤细胞的发生、发展及患者的生存期有关,可作为一个预测NSCLC患者诊断及治疗的重要的分子标志物。     

细胞自噬在吉非替尼治疗非小细胞肺癌中的作用及其机制研究

目的:观察吉非替尼对非小细胞肺癌细胞自噬的影响,并探讨其机制。方法:将BalB/CA-nu品系裸小鼠分成两组,各组20只,均造肺癌模型,其中吉非替尼治疗组小鼠在肺癌组模型的基础上给予吉非替尼25mg/kg 14d,停药后剖杀。取组织切片,通过免疫荧光、RT-PCR以及Western blot的试验方法检测自噬相关基因Beclin1和MAPLC3的表达。结果:免疫荧光、RT-PCR以及Western blot的试验方法检测均发现肺癌组小鼠组织中Beclin1和MAPLC3表达较低,而在吉非替尼处理组中,Beclin1和MAPLC3的表达明显升高,差异有统计学意义。结论:吉非替尼可以通过增强细胞自噬从而发挥对非小细胞肺癌的抑制作用。     

survivin在非小细胞肺癌中的表达及其与bc1-2、p63表达的关系

目的:探讨survivin在非小细胞肺癌组织(non small cell lung cancer,NSCLC)中的表达,及其与bc 1 2、p63蛋白表达的相关性。方法:应用二步法免疫组织化法,检测survivin、bc 1-2、p63蛋白在60例NSCLC组织和20例正常肺组织中的表达。结果:肺癌组织中的survivin蛋白阳性率(56．67%)明显高于正常肺组织15%),有显著性差异;(p＜0．05)Ⅲ期surviving蛋白阳性表达率72．73%(16/22)明显高于Ⅰ Ⅱ期survivin47．37%(18/38)。有显著差异;(p＜0．05)survivin蛋白表达与患者年龄、病理类型、组织分化程度,淋巴结转移情况无关(P＞0．05)NSCLC组织bc 1-2蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为66．67% (18/27)和48．48%(16/33),两者比较,差异有显著性(P＜0．05);p63蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为53．33%(16/30)和60%(18/30),两者比较,差异有显著性(P＜0．05)survivin,蛋白与bc 1-2蛋白的表达呈正相关。survivin蛋白与p63蛋白的表达呈正相关。结论:survivin在NSCLC组织中表达上调,通过抑制细胞凋亡,在NSCLC的发生和发展中起到重要作用。survivin,bc 1-2与p63它们分别在肺癌发生发展过程中不同途径上抑制肺癌细胞的凋亡,对肺癌早期诊断有一定的意义。对3种蛋白进行联合检测,更有利于肺癌的早期诊断和判断肺癌的分化程度、临床分期、淋巴结是否转移及病人的预后。survivin与bc1-2及survivin与p63可能起协同作用,并可能会成为NSCLC基因治疗的新靶点。     

ERCC1和RRM1在非小细胞肺癌组织中的表达及意义

目的:观察非小细胞肺癌中ERCC1和RRM1表达,并探讨其临床意义。方法:选择本院及西安交通大学第一附属胸外二科于2013年1月-2013年6月收治的经术后病理证实为非小细胞癌肺癌患者40例作为研究对象,均采取免疫组化技术测定组织中ERCC1和RRM1表达水平,并分析ERCC1和RRM1表达水平与患者年龄、病理分期、是否淋巴结转移等相关因素之间的关系。结果:40例非小细胞肺癌患者中,ERCC1表达阴性28例(70.0%),阳性12例(30.0%);RRM1表达阴性9例(22.5%),阳性31例(77.5%)。ERCC1和RRM1表达阴性非小细胞肺患者生存期均优于表达阳性患者,均P0.05。患者非小细胞癌TNM分期及淋巴结转移转移情况与ERCC1及RRM1表达情况具有相关性,均P0.05。结论:非小细胞肺癌ERCC1和RRM1表达水平测定有助于预后情况,具有重要临床价值。     

Girdin 表达与非小细胞肺癌侵袭转移及预后的关系

目的:探讨肌动蛋白结合蛋白Girdin与非小细胞肺癌(Non small cell lung cancer,NSCLC)侵袭转移的关系及其对预后的影响。方法:应用免疫组织化学法检测167例非小细胞肺癌患者的病理组织标本中Girdin蛋白和MMP-9的表达。结果:在167例组织标本中Girdin蛋白高表达率为38.9%,其表达水平与患者分期、淋巴结转移、远处转移及生存状况密切相关,差异有统计学意义(P0.05),而与患者性别、年龄、吸烟指数、评分、病理类型及分化程度均无关(P均0.05)。Girdin蛋白的高表达往往伴有MMP-9的高表达,两者显著相关,且差异有统计学意义(P0.05)。Kaplan-Meier单因素生存分析显示Girdin高表达为非小细胞肺癌患者预后的不良因素(P0.05)。COX多因素回归分析显示Girdin的表达水平和分期是判断预后的独立指标(P0.05)。结论:Girdin蛋白在非小细胞肺癌的侵袭和转移中可能发挥着重要的作用,在判断非小细胞肺癌患者预后方面具有一定的价值。     

The Prognostic Value of SOX2 Expression in Non-Small Cell Lung Cancer: A Meta-Analysis

Objective

To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients.

Methods

Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified up to May 2013. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between SOX2 expression and these clinical parameters.

Results

A total of eight studies met the inclusion criteria. Analysis of these data showed that SOX2 expression was positively associated with squamous histology, (pooled OR = 5.26, 95% CI: 1.08–25.6, P = 0.040). Simultaneously, we also found that SOX2 expression was positively associated with overall survival (pooled HR = 0.65, 95% CI: 0.47–0.89, P = 0.007, random-effect).

Conclusions

SOX2 expression in tumor is a candidate positive prognostic biomarker for NSCLC patients.     

Pokemon在小细胞肺癌中的表达及临床意义

目的:检测Pokemon在小细胞肺癌(SCLC)中的表达情况,并探讨其在SCLC发生、发展中的作用及临床意义。方法:应用SP免疫组化方法检测Pokemon在52例SCLC肿瘤组织及20例病灶旁正常组织中的表达。结果:Pokemon在正常肺组织中不表达,52例SCLC组织中,35例呈阳性表达,占67.3%。Pokemon的表达与SCLC患者的性别、年龄、吸烟、淋巴结转移情况均无关(P0.05),而与TNM分期显著相关(P0.05)。Pokemon阳性表达者生存期明显短于阴性表达者,二者比较差异有统计学意义(P0.05)。单因素分析结果显示TNM分期、Pokemon的表达与SCLC患者的预后相关;多因素分析结果显示仅Pokemon的表达与SCLC患者的预后显著相关(P=0.013)。结论:Pokemon在SCLC组织中呈高表达,预示SCLC患者的预后较差,Pokemon表达可能作为SCLC的独立预后预测因素。     

CD133 蛋白在非小细胞肺癌组织中的表达及其与临床病理参数及预后的关系

目的:研究CD133蛋白在非小细胞肺癌(NSCLC)组织中的表达及其与临床病理参数及预后的关系。方法:选择2011年4月~2012年4月间我院收治的42例NSCLC的临床资料,采用免疫组织化学染色法检测癌组织和其中30例癌旁边正常组织CD133的表达,并分析其与肺癌临床病理参数及预后的关系。结果:癌症组织CD133蛋白阳性表达率为57.1%,高于癌旁边正常组织的16.7%,差异有统计学意义(P均0.05);CD133蛋白阳性表达与NSCLC患者年龄、性别以及肿瘤大小、肿瘤位置、组织学类型、组织分化程度以及不同临床分期无关(均P0.05),与淋巴结转移有关,差异有统计学意义(P0.05);CDD133阳性及阴性患者近3年生存率比较,1年生存率比较差异不显著(P0.05),2、3年生存率比较,差异显著有统计学意义(P0.05)。结论:CD133蛋白在NSCLC组织中的高表达,且与NSCLC转移及预后密切相关,对于患者临床特征及预后的关系具有重要的研究价值。     

Dickkopf-1 Is Oncogenic and Involved in Invasive Growth in Non Small Cell Lung Cancer

Dickkopf-1 (DKK1) is an inhibitor of the Wnt/β-catenin signaling pathway. However, the role of DKK1 in the progression of non small cell lung cancer (NSCLC) is not fully understood. In this study, RT-PCR and Western blot were used to examine the expression of DKK1 in a panel of ten human NSCLC cell lines and NSCLC tissues. DKK1 expression was highly transactivated in the great majority of these cancer lines. The expression of DKK1 was upregulated on both mRNA and protein levels in NSCLC tissues compared with the adjacent normal lung tissues. Immunohistochemistry and immunofluoresence revealed that DKK1 was mainly distributed in the cytoplasm in both carcinoma tissues and cell lines. DKK1 protein expression was also evaluated in paraffin sections from 102 patients with NSCLC by immunohistochemistry, and 65(63.73%)tumors were DKK1 positive. Relative analysis showed a significant relationship between DKK1 positive expression and lymph node metastasis(P<0.05). Patients with DKK1-positive tumors had poorer DFS than those with negative ESCC (5-year DFS; 15.4% versus 27%, P = 0.007). To further explore the biological effects of DKK1 in NSCLC cells, we over-expressed DKK1 in NSCLC 95C cell using eukaryotic expression vector pCMV-Tab-2b and performed a knockdown of DKK1 in LTEP-a-2 cell using a short hairpin RNA expression vector pSilencer 5.1. DKK1 did not have any effect on proliferation, but seemed to play a role in migration and invasion capability. Overexpression of DKK1 promotes migratory and invasive activity of 95C, while DKK1 knockdown resulted in the suppression of migration and invasion potentials of LTEP-a-2 cell. Taken together, these results indicate that DKK1 may be a crucial regulator in the progression of NSCLC. DKK1 might be a potential therapeutic target in NSCLC.     

非小细胞肺癌患者K-ras基因突变与预后的相关性分析

目的:探讨非小细胞肺癌(NSCLC)患者K-ras基因突变与预后的相关性。方法:回顾分析2006年3月~2008年7月江西省肿瘤医院收治的92例NSCLC患者的临床资料,所有患者均采用蝎形探针扩增阻遏突变系统(ARMS)法行K-ras基因突变检测。结果:92例NSCLC患者中,11例K-ras基因突变阳性,阳性率为11.96%,包括Gly12Cys(GGTTGT)突变3例、Gly12Val(GGTGTT)突变2例、Gly12Ala(GGTGCT)突变2例、Gly12Arg(GGTCGT)突变2例、Gly12Cys(GGTTGT)突变与Gly12Val(GGTGTT)突变并存1例、Gly12Cys(GGTTGT)突变与Gly12Ala(GGTGCT)突变并存1例;K-ras基因突变阳性组与阴性组之间的患者性别、年龄、病理类型、吸烟史相比,差异无统计学意义(P0.05);K-ras基因突变阳性组Ⅲa~Ⅳ期患者中位生存期显著低于K-ras基因突变阴性组Ⅲa~Ⅳ期患者,差异有统计学意义(P0.05)。结论:NSCLC患者K-ras基因突变阳性率较低,但它可以对NSCLC患者预后产生负性影响。     

非小细胞肺癌组织中CDK2 及β-catenin 的表达

目的:观察非小细胞肺癌组织中CDK2及β-catenin的表达,探讨CDK2及β-catenin与肺癌转移的关系。方法:48例非小细胞肺癌患者分为转移组和未转移组。手术取肺癌组织,分别采用实时荧光定量PCR法和western blot法检测脑组织中CDK2及β-catenin蛋白和mRNA的表达。结果:转移组肺癌组织中CDK2及β-catenin蛋白和mRNA的表达明显高于未转移组(P<0.01)。结论:CDK2及β-catenin与肺癌转移有关。     

MiR-107 and MiR-185 Can Induce Cell Cycle Arrest in Human Non Small Cell Lung Cancer Cell Lines

Background

MicroRNAs (miRNAs) are short single stranded noncoding RNAs that suppress gene expression through either translational repression or degradation of target mRNAs. The annealing between messenger RNAs and 5′ seed region of miRNAs is believed to be essential for the specific suppression of target gene expression. One miRNA can have several hundred different targets in a cell. Rapidly accumulating evidence suggests that many miRNAs are involved in cell cycle regulation and consequentially play critical roles in carcinogenesis.

Methodology/Principal Findings

Introduction of synthetic miR-107 or miR-185 suppressed growth of the human non-small cell lung cancer cell lines. Flow cytometry analysis revealed these miRNAs induce a G1 cell cycle arrest in H1299 cells and the suppression of cell cycle progression is stronger than that by Let-7 miRNA. By the gene expression analyses with oligonucleotide microarrays, we find hundreds of genes are affected by transfection of these miRNAs. Using miRNA-target prediction analyses and the array data, we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6.

Conclusions/Significance

We identified new cell cycle regulating miRNAs, miR-107 and miR-185, localized in frequently altered chromosomal regions in human lung cancers. Especially for miR-107, a large number of down-regulated genes are annotated with the gene ontology term ‘cell cycle’. Our results suggest that these miRNAs may contribute to regulate cell cycle in human malignant tumors.     

Kiss-1 及MVD 在非小细胞肺癌中检测的临床意义及其相关性研究

目的:测定NSCLC组织中kiss-1基因表达、MVD分布,探讨其临床意义及其相关性.方法:应用免疫组化SP法检测56例NSCLC组织中Kiss-1表达及MVD分布情况,分析其与NSCLC的临床病理参数的关系及其相关性.结果:Kiss-1在NSCLC表达低于对照组(P＜0.05),MVD在NSCLC分布明显高于对照组(P＜0.05).Kiss-1与NSCLC的临床分期、淋巴结转移、肿瘤大小有关(P＜0.05).MVD与NSCLC分化程度、临床分期及淋巴结转移、肿瘤大小有关(P＜0.05).Kiss-1阳性组MVD分布明显低于Kiss-1阴性表达组,二者呈负相关(P＜0.05,r=-0.363).结论:Kiss-1及MVD在非小细胞肺癌发生、发展中发挥重要作用,二者存在相关性,联合检测可帮助预测NSCLC的侵袭、转移,判断预后.     

Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients

Immunotherapy approaches using checkpoint blockade, alone, or in combination with tumor antigen vaccination, or adoptive cell transfer, are emerging as promising approaches for the treatment of non-small cell lung cancer (NSCLC). In preparation for upcoming combined immunotherapy approaches in NSCLC, here, we have assessed spontaneous immune responses to XAGE-1b, a tumor specific antigen of the Cancer Testis Antigen group that has been previously reported to be spontaneously immunogenic in the Japanese population, in a cohort of Caucasian patients with NSCLC. We found spontaneous serological responses to XAGE-1b in 9% of the patients. Importantly, these responses were limited to, and represented 13% of, patients with adenocarcinoma tumors, the most frequent histological subtype, for which immunotherapy approaches are under development. Using a set of overlapping peptides spanning the entire XAGE-1b protein, and in support of the serological data, we detected significant XAGE-1b specific CD4⁺ T cell responses in all XAGE-1b seropositive patients and identified several CD4⁺ T cell epitopes. Altogether, our results support the relevance of the XAGE-1b antigen in Caucasians NSCLC patients with adenocarcinoma, and the implementation of future immunotherapies exploiting the high immunogenicity of the antigen in this patient population.     

Kiss-1及MVD在非小细胞肺癌中检测的临床意义及其相关性研究

目的：测定NSCLC组织中kiss-1基因表达、MVD分布,探讨其临床意义及其相关性。方法：应用免疫组化SP法检测56例NSCLC组织中Kiss-1表达及MVD分布情况,分析其与NSCLC的临床病理参数的关系及其相关性。结果：kiss-1在NSCLC表达低于对照组（P〈0.05）,MVD在NSCLC分布明显高于对照组（P〈0.05）。Kiss-1与NSCLC的临床分期、淋巴结转移、肿瘤大小有关（P〈0.05）。MVD与NSCLC分化程度、临床分期及淋巴结转移、肿瘤大小有关（P〈0.05）.Kiss-1阳性组MVD分布明显低于Kiss-1阴性表达组,二者呈负相关（P〈0.05,r=-0.363）。结论：Kiss-1及MVD在非小细胞肺癌发生、发展中发挥重要作用,二者存在相关性,联合检测可帮助预测NSCLC的侵袭、转移,判断预后。     

The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer

Although notable progress has been made in the treatment of non-small-cell lung cancer (NSCLC) in recent years, this disease is still associated with a poor prognosis. Despite early-stage NSCLC is considered a potentially curable disease following complete resection, the majority of patients relapse and eventually die after surgery. Adjuvant chemotherapy prolongs survival, altough the absolute improvement in 5-year overall survival is only approximately 5%.Trying to understand the role of genes which could affect drug activity and response to treatment is a major challenge for establishing an individualised chemotherapy according to the specific genetic profile of each patient. Among genes involved in the DNA repair system, the excision repair cross-complementing 1 (ERCC1) is a useful markers of clinical resistance to platinum-based chemotherapy. In the International Lung Cancer Trial (IALT) adjuvant chemotherapy significantly prolonged survival among patients with ERCC1 negative tumors but not among ERCC1-positive patients. BRCA1 and ribonucleotide reductase M1 (RRM1), two other key enzymes in DNA synthesis and repair, appear to be modulators of drug sensitivity and may provide additional information for customizing adjuvant chemotherapy.Several clinical trials suggest that overexpression of class III β-tubulin is an adverse prognostic factor in cancer since it could be responsible for resistance to anti-tubulin agents. A retrospective analysis of NCIC JBR.10 trial showed that high tubulin III expression is associated with a higher risk of relapse following surgery alone but also with a higher probability of benefit from adjuvant cisplatin plus vinorelbine chemotherapy.Finally, the use of gene expression patterns such as the lung metagene model could provide a potential mechanism to refine the estimation of a patient’s risk of disease recurrence and could affect treatment decision in the management of early stage of NSCLC.In this review we will discuss the potential role of pharmacogenomic approaches to guide the medical treatment of early stage NSCLC.Key Words: NSCLC, adjuvant treatment, molecular markers, ERCC1, RRM1, β-tubulin, EGFR.     

The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis

Objectives

Phosphorylated AKT (p-AKT), constitutive activation of AKT, is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). However, the available results of p-AKT expression in NSCLC are heterogeneous. Therefore, a meta-analysis of published researches investigating the prognostic relevance of p-AKT expression in patients with NSCLC was performed.

Materials and Methods

A literature search via PubMed, EMBASE and CNKI (China National Knowledge Infrastructure) databases was conducted. Data from eligible studies were extracted and included into meta-analysis using a random effects model.

Results

A total of 1049 patients from nine studies were included in the meta-analysis. Nine studies investigated the relationship between p-AKT expression and overall survival using univariate analysis, and five of these undertook multivariate analysis. The pooled hazard ratio (HR) for overall survival was 1.49 (95% confidence interval (CI): 1.01-2.20) by univariate analysis and 1.02 (95% CI: 0.54-1.95) by multivariate analysis.

Conclusion

Our study shows that positive expression of p-AKT is associated with poor prognosis in patients with NSCLC. However, adequately designed prospective studies need to perform.     

4．1B蛋白表达与非小细胞肺癌进展的关系

目的：探讨4．1B蛋白表达与非小细胞肺癌（NSCLC）进展的关系。方法：收集166例临床手术切除、石蜡包埋的原发NSCLC组织,免疫组化检测4．1B蛋白表达,分析其与NSCLC进展的关系。结果：26例4．1B蛋白表达于细胞膜上。69例4．1B蛋白表达缺失,71例胞浆表达。包括胞浆表迭在内,4．1B蛋白异常表达率为84．34％。肿瘤最大直径≤3cm组、未转移组、临床分期I和II期组4．1B蛋白胞膜表达阳性率分别高于肿瘤最大直径〉3cm组、转移组、III和Ⅳ期组,差异有统计学意义（P〈0．0．1）,但4．1B细胞浆表达阳性率在各组间差异无统计学意义（P〉0．05）。结论：在NSCLC组织内,4．1B蛋白存在表达缺失现象,也存在异常定位现象。表达于细胞膜的4．1B蛋白在NSCLC发展过程中可能发挥抑制作用,其表达缺失可能促进肿瘤进展。